Pregnancy and sickle cell disease: an overview of complications and suggested perinatal care

dc.contributor.authorMoukalled, Nour M.
dc.contributor.authorBou-Fakhredin, Rayan
dc.contributor.authorTaher, Ali T.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDivision of Hematology Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:44:22Z
dc.date.available2025-01-24T11:44:22Z
dc.date.issued2022
dc.description.abstractIntroduction: Pregnancy in women with sickle cell disease (SCD) has been identified as high risk owing to increased incidence of materno-fetal complications across various studies and reports. These complications include consequences related to the underlying hemoglobinopathy; chronic anemia/associated inflammation, and pregnancy related including the risk for thromboembolism, bleeding and maternal mortality. Outcomes of neonates born to women with SCD has been suboptimal over the years with recent improvement due to strict monitoring, preventive and therapeutic measures. Much is yet to be unraveled regarding the optimal management of women with SCD during pregnancy, identifying target hemoglobin, delivery mode or timing among others. Areas covered: This review includes a summary of available data of the maternal and fetal outcomes; in addition to current recommendations for monitoring and management of women with SCD during pregnancy. Expert opinion: To have a successful pregnancy, women should be closely monitored, and interventions provided as needed to guarantee adequate management of anemia, as well as prevention, diagnosis and management of disease. They should also be educated regarding their reproductive health, emphasizing that pregnancy is possible, and achieving optimal results depends on providing adequate care in a health care facility with expertise in high-risk pregnancies and SCD. © 2022 Informa UK Limited, trading as Taylor & Francis Group.
dc.identifier.doihttps://doi.org/10.1080/17474086.2022.2151432
dc.identifier.eid2-s2.0-85143080374
dc.identifier.pmid36413684
dc.identifier.urihttp://hdl.handle.net/10938/30440
dc.language.isoen
dc.publisherTaylor and Francis Ltd.
dc.relation.ispartofExpert Review of Hematology
dc.sourceScopus
dc.subjectFertility
dc.subjectFetal
dc.subjectMaternal
dc.subjectPerinatal care
dc.subjectPregnancy
dc.subjectSickle cell disease
dc.subjectAnemia, sickle cell
dc.subjectChild
dc.subjectFemale
dc.subjectHumans
dc.subjectIncidence
dc.subjectInfant, newborn
dc.subjectPregnancy complications, hematologic
dc.subjectAdult
dc.subjectFemale fertility
dc.subjectFetus
dc.subjectFetus disease
dc.subjectFetus heart rate
dc.subjectFetus outcome
dc.subjectHealth care facility
dc.subjectHigh risk pregnancy
dc.subjectHospitalization
dc.subjectHuman
dc.subjectIntrapartum care
dc.subjectNewborn
dc.subjectPractice guideline
dc.subjectPregnancy complication
dc.subjectPregnant woman
dc.subjectPrenatal care
dc.subjectPrenatal period
dc.subjectReproductive health
dc.subjectReview
dc.subjectSickle cell anemia
dc.subjectComplication
dc.titlePregnancy and sickle cell disease: an overview of complications and suggested perinatal care
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022-2071.pdf
Size:
727.02 KB
Format:
Adobe Portable Document Format